Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Project # Project Title Research Focus Area Research Program Administering IC Sort descending Institution(s) Investigator(s) Location(s) Year Awarded
1R43DA050380-01
Neurofeedback-EEG-VR (NEVR) System for Non-opioid Pain Therapy Cross-Cutting Research Small Business Programs NIDA QUASAR, INC. ROBERTS, BROOKE San Diego, CA 2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

Pain is one of the most common and debilitating symptoms of a wide range of injuries and diseases. Safe and effective alternatives for treating pain that reduce dependence on opioids are, therefore, a primary goal of the NIH. This project proposes a non-invasive, non-pharmacological alternative to treat pain by combining an innovative electroencephalography (EEG)-based Neurofeedback (NF) solution in an immersive virtual reality (VR) environment. NF and VR have been shown to independently produce ameliorative effects on pain, and it is hypothesized that an NF training in VR would have synergistic effects, as VR would distract from pain perception to improve patient compliance in more engaging NF protocols that improve their ability to control pain perception. In the scope of this project, we will initially focus our work on chronic low back pain (cLBP), as this is a growing segment of chronic pain sufferers with a 39 percent worldwide lifetime prevalence, and whose sufferers have historically been heavy users of opiates; later stages of this project will expand this application to address other forms of pain.

1K01DA058750-01
Leveraging mHealth to Increase Health Equity Among Black Individuals with OUD and Commonly Occurring Mental Health Disorders Cross-Cutting Research Training the Next Generation of Researchers in HEAL NIDA WASHINGTON UNIVERSITY SZLYK, HANNAH Saint Louis, MO 2023
NOFO Title: HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)
NOFO Number: PAS-22-206
Summary:

This project provides protected time for training and research activities that are required for an independent scientific career in the development, testing, and implementation of cutting-edge digital therapies and tools (such as smartphone apps and other web-based resources) that can promote health equity in treatment of opioid use disorder (OUD). The research will adapt and test digital overdose prevention and recovery support interventions for Black Americans with co-occurring OUD and mental illness. 

2R44DA049640-02
Virtual Reality as a Opioid Sparing Intervention for Acute Postoperative Pain Management Cross-Cutting Research Small Business Programs NIDA APPLIEDVR, INC MADDOX, WILLIAM TODD (contact); AYAD, SABRY ; SUK, MICHAEL Los Angeles, CA 2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

Millions of Americans undergo surgery each year, with fewer than half of patients reporting adequate postoperative pain relief and approximately 75 percent reporting moderate to severe postoperative pain. Gaps in postoperative pain management that lead to the unnecessary introduction and over-prescription of opioids continue to exacerbate the opioid crisis, but virtual reality (VR) has been demonstrated to be an effective strategy for pain management. This project will enhance and improve the functionality of a VR-based technology, AppliedVR, to provide acute perioperative pain management through a new software-based VR medical device, RelieVRx™. As a non-opioid alternative intended to reduce postoperative pain, RelieVRx can potentially reduce the need for and utilization of opioids in the postoperative setting.

1U2CDA057717-01
HD2A Research Adoption Support Center (RASC) Cross-Cutting Research Translating Data 2 Action to Prevent Overdose NIDA STANFORD UNIVERSITY MCGOVERN, MARK P (contact); BECKER, SARA J; BECKER, WILLIAM C; BROWN, C HENDRICKS Redwood City, CA 2022
NOFO Title: HEAL Initiative: HEAL Data2Action Research Adoption Support Center (U2C Clinical Trial Optional)
NOFO Number: RFA-DA-22-050
Summary:

This project creates the HEAL Data2Action Research Adoption Support Center to support the HEAL Data2Action Innovation Projects. It will provide supportive evidence for prevention and treatment practices, form implementation strategies, assess outcomes, obtain feedback from the projects, and assess readiness for scalability. This center will offer on-demand technical assistance, host a learning collaborative, harmonize dissemination and implementation data, provide implementation support, and help with stakeholder engagement. The research will also catalogue evidence-based and emerging opioid use disorder and pain management practices as a resource to the field. The center will address timely, high-priority implementation challenges.

2R44DA043325-02
SENSITIVE AND PORTABLE PHYSICIAN OFFICE-BASED URINE ANALYZER TO TACKLE PRESCRIPTION DRUG ABUSE Cross-Cutting Research Small Business Programs NIDA BreviTest Technologies, LLC Heffernan, Michael John HOUSTON, TX 2019
NOFO Title: PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-18-574
Summary:

Current drug-screening immunoassays use benchtop analyzers that require experienced personnel, time, and a laboratory setup. Physicians without access to in-house testing have to send out patient samples for screening, resulting in unacceptable delays in the treatment of patients who are potentially suffering from chronic pain. This project, a partnership with BreviTest Technologies, LLC, aims to develop a low-cost, point-of-care (POC) urine drug testing (UDT) device to detect opioids. The goal is for a portable platform to deliver quantitative performance similar to a standard laboratory test for opioids within a 10-minute run time. If successful, this will provide a technology capable of performing rapid quantifications of urine drug levels in a physician’s office, providing an invaluable tool to render more effective pain management dosing to patients, thus paving the way toward lower toxicity and a better quality of life.

2R44DA050397-02
Development of cannabinoid-opioid combination with opioid sparing and synergistic analgesic effects to prevent opioid use disorder and overdose Cross-Cutting Research Small Business Programs NIDA BDH PHARMA, LLC BRIONES, MARISA Valley Village, CA 2021
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional
NOFO Number: RFA-DA-19-019
1R43DA050338-01
A universal approach for improving the limit of detection for fentanyl and fentanyl derivatives in urine Cross-Cutting Research Small Business Programs NIDA CERES NANOSCIENCES, LLLP LEPENE, BENJAMIN SCOTT MANASSAS, VA 2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
1R43DA058430-01
Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy Cross-Cutting Research Small Business Programs NIDA OPALGENIX, INC. PLUMP, STEVEN R (contact); SADHASIVAM, SENTHILKUMAR Carmel, IN 2023
NOFO Title: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-021
Summary:

There is an urgent and unmet clinical need for a reliable technology to prevent maternal opioid use relapse and neonatal opioid withdrawal syndrome (NOWS) in their infants. This project aims to assess risk for these outcomes based on individual genetic and clinical factors. The research will expand previous studies of genetic and clinical predictors of opioid-related adverse outcomes. The goal is to develop a risk predictor algorithm and software tool for use in an electronic health record, toward personalized risk assessment and prevention of maternal relapse and NOWS. 

1K23DA058751-01
Building and Implementing Best Practices for Buprenorphine Initiation in the Setting of Fentanyl Use Cross-Cutting Research Training the Next Generation of Researchers in HEAL NIDA UNIVERSITY OF WASHINGTON BHATRAJU, ELENORE Seattle, WA 2023
NOFO Title: HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)
NOFO Number: PAS-22-207
Summary:

This project provides protected time for training and research activities that are required for an independent scientific career in delivering evidence-based treatments for people with opioid use disorder. The increasing presence of fentanyl in the drug supply creates challenges for the use of buprenorphine, because both patients and physicians want to avoid causing withdrawal. This research will interview both patients and physicians to understand their concerns and experiences and work with them to develop a buprenorphine induction toolkit to help balance the advantages of buprenorphine treatment against concerns about the potential presence of unknown fentanyl. 

2R44DA041912-03
COMPLETION OF IND-PACKAGE FOR A NOVEL, NON-NARCOTIC PAINKILLER Cross-Cutting Research Small Business Programs NIDA Blue Therapeutics, Inc. Yekkirala, Ajay S CAMBRIDGE, MA 2019
NOFO Title: PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
NOFO Number: PA-17-302
Summary:

Opioids like morphine and hydrocodone are generally the most effective therapeutics for treatment of moderate to severe pain. However, their use is limited by serious side effects: tolerance, constipation, respiratory depression, physical dependence, and high addictive potential. Alternative pain relievers with the analgesic potency of conventional opioids, but devoid of narcotic side effects, are an immediate need. The goal of this project is to develop and commercialize an alternative to conventional opioid analgesics with reduced side effects and without the addictive properties common to mu-opioid agonists, targeting a new molecule in the central nervous system. This project will perform the necessary preliminary studies to prepare this new molecule for an investigational new drug application with the FDA.

1U24DA057650-01
HEAL Data2Action Modeling and Economic Resource Center Cross-Cutting Research Translating Data 2 Action to Prevent Overdose NIDA WEILL MEDICAL COLL OF CORNELL UNIV SCHACKMAN, BRUCE R (contact); LINAS, BENJAMIN P; MCCOLLISTER, KATHRYN E New York, NY 2022
NOFO Title: HEAL Initiative: HEAL Data2Action Modeling and Economic Resource Center (U24 Clinical Trial Optional)
NOFO Number: RFA-DA-22-049
Summary:

This project creates the HEAL Data2Action Modeling and Economic Resource Center that will conduct research as well as support the HEAL Data2Action Innovation Projects with expertise and consultation about simulation modeling and economic evaluation methods. The consultation service will advise on how to select and use various research methods, including economic evaluation, simulation modeling, advanced statistical analysis, behavioral economics, treatment program organization research, and cost analysis. The center will use a dynamic simulation model of opioid use disorder to enhance data-driven decision making. The center will also provide online training resources, tools, and other resources to assess a variety of economic aspects related to the HEAL Data2Action Innovation Projects.

1R43DA049617-01
At-Home Virtual Reality Guided Imagery Intervention for Chronic Pain Cross-Cutting Research Small Business Programs NIDA LIMBIX HEALTH, INC. LEWIS, BENJAMIN (contact); RICHEIMER, STEVEN H Palo Alto, CA 2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

Chronic pain affects more than 100 million adults in the United States, resulting in disability, loss of work productivity, and overall reductions in health, making chronic pain a major public health problem with an economic burden estimated at $560–635 billion annually. Opioids, the most frequently prescribed class of drugs to control pain, lack evidence supporting their long-term efficacy and carry a 15% to 26% risk of misuse and abuse among pain patients. Guided imagery (GI) is an effective non-pharmacological intervention for reducing pain, but its effectiveness is limited by patients’ imaging abilities. This project will develop and assess the feasibility of an at-home virtual reality system, Limbix VR Kit, to reduce chronic pain and opioid reliance, as well as improve other functional outcomes, by delivering an immersive GI experience.

2R44DA053078-02
Developing and Testing the Opioid Rapid Response System Cross-Cutting Research Small Business Programs NIDA REAL PREVENTION, LLC HECHT, MICHAEL (contact); CHOI, HYE JEONG Clifton, NJ 2023
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
NOFO Number: PA-22-177
Summary:

Reversing an opioid overdose requires a rapid response not available through standard emergency procedures. The Opioid Rapid Response System recruits and trains citizen responders to reverse overdoses with naloxone. It uses widely disseminated smart phone apps linking responders to an overdose through the 911 system. This project will complete the development of this system, test how well it works to reverse an opioid overdose, and prepare to share it widely. 

1R43DA050349-01
A Novel Chemokine Receptor Antagonist to Block Opioid Reinforcement, Relapse and Physical Dependence Cross-Cutting Research Small Business Programs NIDA CREATIVE BIO-PEPTIDES, INC. RUFF, MICHAEL Potomac, MD 2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

Current agonist treatments for opioid use disorder (OUD) are not adequate to address the opioid crisis and have abuse liability concerns. Chemokines (hormones of the immune system that mediate innate immune inflammation) enhance pain, reduce opioid analgesia, and promote drug-seeking behavior and addiction—giving them a central role at the crossroads of chronic pain and the opioid crisis. So blocking chemokines (rather than opioid receptors) provides an exciting and untested treatment opportunity for pain and OUD. This proposal will assess, in animal self-administration models that mimic human drug-taking, whether a chemokine antagonist peptide R103 reduces morphine intake, as well as if R103 will prevent or blunt naloxone-precipitated withdrawal signs in morphine-dependent rats and stop relapse.

1R61DA059168-01
The Use of Novel Linked Databases to Reduce Postoperative Opioid Use Among Patients Undergoing Inpatient Surgery Cross-Cutting Research Translating Data 2 Action to Prevent Overdose NIDA STANDFORD UNIVERSITY SUN, ERIC (contact); COLQUHOUN, DOUGLAS ALASTAIR Stanford, CA 2023
NOFO Title: HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional)
NOFO Number: RFA-DA-23-057
Summary:

Older adults make up more than half of all surgical patients in the United States, putting them at risk for a range of harmful outcomes including misusing opioids, developing opioid use disorder (OUD), opioid overdose, and surgical complications. This project seeks to understand whether pre-surgery interventions can prevent harmful opioid-related outcomes. The research will combine data from a registry of electronic health records and from Medicare claims data to learn about the relationship between these interventions and opioid-related outcomes including persistent opioid use, OUD, and other harmful outcomes.

1R44DA049631-01
Addressing Opioid Use Disorder with an External Multimodal Neuromodulation Device: Development and Clinical Evaluation of DuoTherm for Opioid-Sparing in Acute and Chronic Low Back Pain. Cross-Cutting Research Small Business Programs NIDA MMJ LABS, LLC BAXTER, AMY LYNN Atlanta, GA 2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

Acute and chronic low back pain are among the most common sources of short- and long-term disability. Fear of pain and disability, or “catastrophizing,” increases opioid use, but is reduced when patients have effective options and feel control over pain. The goal of this project is to develop an opioid-sparing therapeutic consumer device for low back pain, with multiple patient-controlled effective neuromodulatory pain relief options, including vibration, pressure, cold, and heat. After proving that providing a multimodal device is effective for pain, the project will determine whether the availability of an effective home therapy device reduces opioid use for patients with acute and chronic low back pain.

1R43DA049620-01
NeoGUARD: An easy-to-use, low-cost brain monitor for objective screening and treatment of opioid-exposed infants Cross-Cutting Research Small Business Programs NIDA NEUROWAVE SYSTEMS, INC. Zikov, Tatjana None Cleveland Hights, OH 2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

Neonatal Opioid Withdrawal Syndrome (NOWS) affects a growing number of neonates each year due to the ongoing opioid epidemic ravaging the United States. Complex neurobehavioral observation of newborns is the primary modality used. It is subjective and time-consuming by nature, requires significant expertise, and can lead to delays in treatment. The goal of this project is to develop an innovative, low-cost, non-invasive, and easy-to-use brain monitor to objectively assess the severity of withdrawal symptoms in newborns exposed to opioids and provide evidence-based decision support to care providers to improve both short- and long-term developmental outcomes. This device, referred to as NeoGUARD, is based on the continuous, automated, and real-time monitoring of brain function to detect EEG abnormalities shown to be related to NOWS and determine severity to guide pharmacological intervention. This study will focus on the initial prototyping and refinement of the hardware and software, as well as initial evaluations of its use.

1U24DA057612-01
WF DISC: Navigating Data Solutions for Chronic Pain and Opioid Use Disorder Cross-Cutting Research Translating Data 2 Action to Prevent Overdose NIDA WAKE FOREST UNIVERSITY HEALTH SCIENCES ADAMS, MEREDITH C B Winston-Salem, NC 2022
NOFO Title: HEAL Initiative: HEAL Data2Action Data Infrastructure Support Center (U24 Clinical Trial Optional)
NOFO Number: RFA-DA-22-052
Summary:

This project creates the HEAL Data2Action Data Infrastructure Support Center that will conduct research as well as support the HEAL Data2Action Innovation Projects with analytics and support for navigating electronic health records and other “big data” sources, as well as logistical processes related to privacy and ethics. The center will help plan for data collection and assessing outcomes, as well as provide data visualization efforts for various stakeholders. Key support mechanisms include courses, seminars, conferences, trainings, and on-demand technical assistance.

1R01DA057686-01
Fast and Fine: NLP Methods for Near Real-Time and Fine-Grained Overdose Surveillance Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDA UNIVERSITY OF KENTUCKY KAVULURU, VENKATA NAGA RAMAKANTH Lexington, KY 2022
NOFO Title: HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-22-044
Summary:

Timely and accurate surveillance of fatal and non-fatal overdoses is necessary in light of the worsening overdose crisis, but data is rarely available in real-time. Tracking non-fatal overdoses is especially important because patients who overdose once are likely to experience additional and potentially fatal overdoses. This project aims to increase the quality and timeliness of non-fatal overdose data estimates by analyzing clinicians’ notes rather than clinical codes from emergency department and emergency medical services records. The datasets and models produced from this research will be used to build an interactive dashboard with up-to-date, county-level overdose-surveillance estimates for use by Kentucky first responders to aid in rapid allocation of resources.

1R43DA049623-01
Non-invasive Neuromodulation Device for Decreasing Withdrawal Symptoms and Craving during Treatment of Opioid Use Disorder Cross-Cutting Research Small Business Programs NIDA THERANOVA, LLC JAASMA, MICHAEL San Francisco, CA 2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

Opioid use disorder (OUD) can be lethal, with opioid overdose causing more than 115 deaths in the U.S. each day. Although medications are effective at reducing illicit opioid use and overdose deaths, it is well-established that withdrawal and craving are highest in the initial weeks, making this a high-risk period for treatment dropout, relapse, and overdose. Adjunct therapies that can reduce early opioid withdrawal and craving may improve retention in treatment with buprenorphine-naloxone, and recent research has shown that stimulation of a peripheral nerve significantly modulates withdrawal- and craving-related responses for opioids and other drugs. This project will test the effectiveness of the EMPOWER Neuromodulation System, a portable, non-invasive transcutaneous electrical nerve stimulation (TENS) device developed by TheraNova for the treatment of OUD.

2R44DA048689-02
Beacon-OUD: Behavioral Economic Screening Tool of Opioid Use Disorder (OUD) for Use in Clinical Practice Cross-Cutting Research Small Business Programs NIDA BEAM DIAGNOSTICS, INC. SNIDER, SARAH EMILY Roanoke, VA 2023
NOFO Title: PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-21-259
Summary:

Current clinical screening measures for opioid misuse are underused and susceptible to bias. This project will develop Beacon-OUD, a digital opioid misuse assessment. The tool generates an automated, standardized score, preventing potential judgements related to patient’s status and circumstances, limiting stigma. The research will further advance Beacon-OUD into a commercial product for use both as a stand-alone tool and as an electronic health record-integrated solution to encourage objective opioid misuse screening in large health care systems. 

1R43DA050358-01
A Project to Test The Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders Cross-Cutting Research Small Business Programs NIDA MINDLIGHT, LLC SCHIFFER, FREDRIC (contact); TEICHER, MARTIN H Newton, MA 2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

This project aims to demonstrate the safety and effectiveness of a novel treatment for opiate addiction using a technique called photobiomodulation, application of light to the forehead. The treatment consists of using a 4-minute application of transcranial photobiomodulation, near-infrared mode, through a supra-luminous LED, to one side of the forehead over the brain hemisphere that has been determined to have a more positive emotional valence. The study will examine differences in opioid cravings, anxiety, depression, and opioid use between participants receiving the treatment and those receiving a sham treatment. We will evaluate patients weekly for safety and efficacy for 3 weeks post-treatment. In Aim II, a highly-regarded product engineer will work with the company to design a marketable product that may have patentable elements.

1R61DA059169-01
Leveraging Data to Action: Accelerating Emergency Department OUD Care by Improving Data Access and Infrastructure Cross-Cutting Research Translating Data 2 Action to Prevent Overdose NIDA YALE UNIVERSITY VENKATESH, ARJUN KRISHNA (contact); HAWK, KATHRYN; TAYLOR, RICHARD ANDREW New Haven, CO 2023
NOFO Title: HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional)
NOFO Number: RFA-DA-23-057
Summary:

Emergency departments (EDs) are key settings for identifying and treating opioid use disorder (OUD), but EDs are underused for this purpose. This project aims to develop a data system that automates and integrates electronic health record and administrative data from EDs into the Clinical Emergency Department Registry, partnering with the American College of Emergency Physicians. The research will assess the digital readiness of ED systems before developing and deploying the enhanced ED OUD data infrastructure. This research aims to guide near-real time hospital quality improvement initiatives, toward development of a web-based, near-real time dashboard that can be used in EDs across the country.

1R43DA049684-01
Non-intrusive detection of temporary neurologic impairment by opioids Cross-Cutting Research Small Business Programs NIDA ZXEREX CORPORATION BESSERMAN, RICHARD Scottsdale, AZ 2019
NOFO Title: PHS 2018-02 Omnibus Solicitation of the NIH for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
NOFO Number: PA-18-573
Summary:

With the exception of the Breathalyzer for alcohol, there is currently no available technology that can immediately identify neurologic impairment related to the use of licit or illicit drugs. The presently available methods for detecting opioids—which rely upon analysis of urine, blood, saliva, or hair—are expensive, time-consuming to implement, and can take days to deliver actionable information to meet the “fitness-for-duty” concerns of employers as well as the needs for immediate detection of drug use in the drug rehabilitation and public safety fields. This project intends to develop a non-invasive means of identifying temporary neurological impairment from prescription opioids using analysis of involuntary eye movements. The resultant biometric signature of opioid impairment will be incorporated into Zverex’s existing product library of oculomotor biosignatures, such as marijuana impairment and fatigue.

1R01DA057630-01
Predicting Fatal and Non-Fatal Overdose in Los Angeles County with Rapid Overdose Surveillance Dashboard to Target Street-Based Addiction Treatment and Harm Reduction Services Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDA UNIVERSITY OF CALIFORNIA LOS ANGELES SHOVER, CHELSEA LEIGH (contact); GOODMAN, DAVID Los Angeles, CA 2022
NOFO Title: HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-22-044
Summary:

Effective overdose prevention requires timely, location-specific data to efficiently direct resources and interventions as well as to inform healthcare policy. However, rarely is such information available, resulting in responses that are frequently too late. This project will partner with local government agencies from Los Angeles County, California, to rapidly acquire and analyze information in near real-time from multiple sources to identify overdose hotspots and determine overdose metrics. This information will be used to develop a publicly available Rapid Overdose Surveillance Los Angeles online dashboard with built-in analytics. The dashboard will help determine the scope and specifics of overdose and opioid use in Los Angeles County to help target response and guide mobile addiction treatment and harm reduction services.